GlassScriptPhysician profile
Hannah L Lanctot
NPI 1437789534
$2,605.09
in general payments reported to CMS, 2019-2025
25 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $368 · 2023: $817 · 2024: $565 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,876.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $502.02 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $445.25 | 2021-2025 | Farxiga, Wainua, Andexxa |
| Novartis Pharmaceuticals Corporation | $376.20 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $178.93 | 2021 | |
| Boston Scientific Corporation | $153.43 | 2022-2025 | Watchman Flx, Bodyguardian |
| E.R. Squibb & Sons, L.L.C. | $100.77 | 2022-2025 | Eliquis, Camzyos |
| Pfizer INC. | $100.60 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $89.93 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $85.46 | 2024-2025 | Onpattro |
| Heartflow, INC. | $84.93 | 2022-2025 | Ffrct |
| Janssen Pharmaceuticals, INC | $64.54 | 2022-2024 | Xarelto |
| Amgen INC. | $63.35 | 2022-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $54.54 | 2022-2023 | |
| Edwards Lifesciences Corporation | $46.57 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.80 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.68 | 2023 | Verquvo |
| Horizon Therapeutics Plc | $25.95 | 2021 | |
| Atricure, INC. | $24.66 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.55 | 2021 | |
| Esperion Therapeutics, INC. | $23.48 | 2024 | Nexletol |
| Novo Nordisk INC | $23.02 | 2025 | Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $17.28 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $16.60 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $15.06 | 2023 | Arcalyst |
| Alfasigma USA, INC. | $13.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Lanctot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.